AMEX · IBO
Impact BioMedical Inc.
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
Loading market information…
NASDAQ · TCRT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alaunos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alaunos Therapeutics, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$15.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alaunos Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.46+89.78% vs estimate |
| $4.00K |
| Q3 2024 | Nov 14, 2024 | -$0.70+84.44% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.99+$0.00 (0.0%)
Impact BioMedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.02% below the high.
$28.56$0.00 (0.0%)
VYNE Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.65% below the high.
$23.52$0.00 (0.0%)
Cyclerion Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.38% below the high.
$0.37-$0.02 (-5.95%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.06% below the high.
$9.00+$0.39 (+4.57%)
Polyrizon Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.53% below the high.
$4.15+$0.04 (+0.97%)
Quoin Pharmaceuticals, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.34% below the high.
$0.16-$0.00 (-2.42%)
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
$2.93-$0.03 (-1.01%)
Addex Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 71.91% below the high.
